Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
Mediar Therapeutics
Study ID
NCT07450521
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Adult Male

Eligibility Criteria

Sex
MALE
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • MTX-463 — BIOLOGICAL
    MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.
  • Placebo — OTHER
    Placebo

Study Details

A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.

Key Dates

Start date
Feb 18, 2026
Status verified
Mar 2026
Primary completion
Mar 11, 2026
Completion
Mar 11, 2026

Study Design

Enrollment
8 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: MTX-463
    MTX-463
  • Placebo Comparator: Placebo
    Placebo

Primary Outcome Measure

PK will be evaluated by area under the plasma concentration versus time curve from time zero to t (AUC0-t) of MTX-463 [ Time Frame: 22 Days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Icon Slc CruSalt Lake CityUtah84124-

Find similar trials in Salt Lake City, UT

By research site
Icon Slc Cru· Salt Lake City, UT

Related Studies